ReviewVirchows Archiv : an international journal of pathology2014
Prognostic and predictive biomarkers in lung cancer. A review.
Review in Virchows Archiv : an international journal of pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 90 citations in OpenAlex.
- Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.Journal for immunotherapy of cancer · 2024Article
- Lung Cancer: New Directions in Senior Patients Assessment.Geriatrics (Basel, Switzerland) · 2024Review
- Spatial colocalization and combined survival benefit of natural killer and CD8 T cells despite profound MHC class I loss in non-small cell lung cancer.bioRxiv : the preprint server for biology · 2024Article
- Replication of Real-World Evidence in Oncology Using Electronic Health Record Data Extracted by Machine Learning.Cancers · 2023Article
- Article
- Association between squamous cell carcinoma antigen level and EGFR mutation status in Chinese lung adenocarcinoma patients.Journal of clinical laboratory analysis · 2022Article
- Unraveling the Rewired Metabolism in Lung Cancer Using Quantitative NMR Metabolomics.International journal of molecular sciences · 2022Review
- Regulation of a Novel Splice Variant of Early Growth Response 4 (EGR4-S) by HER+ Signalling and HSF1 in Breast Cancer.Cancers · 2022Article
- The role of salvage surgery in the treatment of a gefitinib-resistant non-small cell lung cancer patient: a case report.Journal of thoracic disease · 2021Article
- An application of machine learning based on real-world data: Mining features of fibrinogen in clinical stages of lung cancer between sexes.Annals of translational medicine · 2021Article
- Electrospray Mediated Localized and Targeted Chemotherapy in a Mouse Model of Lung Cancer.Frontiers in pharmacology · 2021Article
- Identification of a Sixteen-gene Prognostic Biomarker for Lung Adenocarcinoma Using a Machine Learning Method.Journal of Cancer · 2020Article
- Article
- Article
- An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.Annals of translational medicine · 2019Article
- A Simulation Study Comparing Different Statistical Approaches for the Identification of Predictive Biomarkers.Computational and mathematical methods in medicine · 2019Article
- Prophylactic Dermatologic Treatment of Afatinib-Induced Skin Toxicities in Patients with Metastatic Lung Cancer: A Pilot Study.Scientifica · 2019Article
- Classification and mutation prediction from non-small cell lung cancer histopathology images using deep learning.Nature medicine · 2018Article
- An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.Journal of clinical medicine · 2018Review
- A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer.Oncotarget · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In lung cancer, clinically relevant prognostic information is provided by staging. Staging forms the basis for the treatment options and this is briefly summarized in the introduction. Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase are biomarkers used for prediction of chemotherapy and prediction of targeted treatment. Other driver biomarkers in lung cancer (point mutations and rearrangements in specific genes including Her2, BRAF, NUT, MET, ROS1, DDR2, FGFR1, KRAS, and PTEN) might potentially provide additional information for clinical decision making. Owing to the low prevalence of mutations in predictive markers, patient numbers in studies are usually small, with the exception of EGFR. These mutations increase our understanding of the biology of lung cancer. Mutation analysis as a basis for treatment choice can have an impressive clinical impact with dramatic responses. However, as yet the impact of these approaches to overall survival is less striking.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.